Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Neogen Corporation

Healthcare US NEOG

9.65USD
-0.05(0.52%)

Last update at 2026-03-10T20:00:00Z

Day Range

9.429.95
LowHigh

52 Week Range

11.4624.09
LowHigh

Fundamentals

  • Previous Close 9.70
  • Market Cap2928.54M
  • Volume2044338
  • P/E Ratio676.00
  • Dividend Yield-%
  • EBITDA246.76M
  • Revenue TTM929.24M
  • Revenue Per Share TTM4.29
  • Gross Profit TTM 409.20M
  • Diluted EPS TTM0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Income before tax -22.04200M 60.21M 75.27M 72.31M 72.96M
Minority interest - - - 0.00000M 0.00000M
Net income -22.87000M 48.31M 60.88M 59.48M 60.18M
Selling general administrative 201.18M 82.74M 51.20M 44.33M 40.79M
Selling and marketing expenses 141.22M 84.60M 73.44M 69.67M 70.23M
Gross profit 405.95M 243.01M 215.06M 196.28M 191.92M
Reconciled depreciation 88.38M 23.69M 21.04M 18.40M 17.62M
Ebit -50.86200M 34.92M 53.13M 49.13M 50.47M
Ebitda 37.52M 58.62M 74.17M 67.52M 68.09M
Depreciation and amortization 88.38M 23.69M 21.04M 18.40M 17.62M
Non operating income net other -6.76200M 0.32M -0.51500M -1.21000M 0.18M
Operating income 37.52M 34.92M 53.13M 49.13M 50.47M
Other operating expenses 784.93M 468.54M 394.29M 350.65M 346.09M
Interest expense 55.96M 1.27M 22.14M 23.18M 22.49M
Tax provision 0.83M 11.90M 14.39M 12.83M 12.78M
Interest income 3.17M 1.27M 1.61M 5.99M 4.68M
Net interest income -52.79500M 1.27M 1.61M 5.99M 4.68M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.83M 11.90M 14.39M 12.83M 12.78M
Total revenue 822.45M 527.16M 468.46M 418.17M 414.19M
Total operating expenses 368.44M 184.40M 140.89M 128.76M 123.83M
Cost of revenue 416.49M 284.15M 253.40M 221.89M 222.27M
Total other income expense net -59.55700M 25.28M 22.14M 23.18M 22.49M
Discontinued operations - - - - -
Net income from continuing ops -22.87000M 48.31M 60.88M 59.48M 60.18M
Net income applicable to common shares -22.87000M 48.31M 60.88M 59.48M 60.18M
Preferred stock and other adjustments - - - - -
Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Total assets 4554.43M 992.93M 920.19M 797.18M 695.74M
Intangible assets 1605.10M 107.50M 92.32M 66.58M 67.75M
Earning assets - - - - -
Other current assets 53.30M 23.76M 17.84M 14.00M 13.43M
Total liab 1420.21M 105.56M 79.81M 72.00M 57.84M
Total stockholder equity 3134.22M 887.37M 840.38M 725.18M 637.90M
Deferred long term liab 1.51M - 21.92M 18.12M 15.62M
Other current liab 64.19M 37.77M 29.70M 22.84M 19.19M
Common stock 34.60M 17.25M 17.20M 8.47M 8.36M
Capital stock 34.60M 17.25M 17.20M 8.47M 8.36M
Retained earnings 565.04M 587.91M 539.60M 478.72M 419.25M
Other liab 375.72M 27.71M 26.22M 22.60M 19.59M
Good will 3769.75M 255.55M 228.29M 181.10M 171.36M
Other assets 15.22M 4799.03M 2.02M 2.23M 0.14M
Cash 163.24M 381.05M 381.09M 343.67M 267.52M
Cash and equivalents - - - - -
Total current liabilities 145.47M 77.84M 53.60M 48.49M 38.25M
Current deferred revenue 4.62M 5.46M - - -
Net debt 736.76M 605.64M -381.08700M -343.67300M -267.52400M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total 900.00M 986.69M - - -
Other stockholder equity 2567.83M 309.98M 294.95M 257.69M 221.94M
Property plant equipment 198.75M 110.58M 100.45M 78.67M 74.85M
Total current assets 585.93M 626.80M 591.45M 537.41M 449.53M
Long term investments - - - - -
Net tangible assets 3134.22M 887.37M 612.09M 599.62M 518.63M
Short term investments 82.33M 336.58M 305.49M 277.40M 225.84M
Net receivables 153.25M 99.67M 91.82M 84.68M 82.58M
Long term debt 885.44M - - - -
Inventory 133.81M 122.31M 100.70M 95.05M 85.99M
Accounts payable 76.67M 34.61M 23.90M 25.65M 19.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -33.25100M -27.76900M -11.37500M -19.70900M -11.64000M
Additional paid in capital - - - - -
Common stock total equity 34.60M 17.25M 17.20M 8.47M 8.36M
Preferred stock total equity - - - - -
Retained earnings total equity 565.04M 587.91M 539.60M 478.72M 419.25M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3769.75M 2.16M 2.02M 2.23M -15.61800M
Deferred long term asset charges - - - - -
Non current assets total 3968.50M 366.13M 328.74M 259.78M 246.21M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Type yearly yearly yearly yearly yearly
Date 2023-05-31 2022-05-31 2021-05-31 2020-05-31 2019-05-31
Investments 254.25M -34.05500M -28.08100M -51.56900M -98.09900M
Change to liabilities 22.69M 26.50M -3.20600M 13.85M -2.66700M
Total cashflows from investing activities 201.04M -97.22900M -105.56400M -88.78500M -119.14800M
Net borrowings -119.27600M -100.00000M -100.00000M -100.00000M -
Total cash from financing activities -118.08100M 6.81M 33.54M 29.41M 13.90M
Change to operating activities 2.50M 12.23M -3.28000M 6.08M -4.77500M
Net income -22.87000M 48.31M 60.88M 59.48M 60.18M
Change in cash 118.77M -31.12900M 9.33M 24.58M -41.38600M
Begin period cash flow 44.47M 75.60M 66.27M 41.69M 83.07M
End period cash flow 163.24M 44.47M 75.60M 66.27M 41.69M
Total cash from operating activities 41.03M 68.04M 81.09M 85.88M 63.84M
Issuance of capital stock - - - - -
Depreciation 88.38M 23.69M 21.04M 18.40M 17.62M
Other cashflows from investing activities 12.55M -38.74500M -50.77100M -13.16400M -6.38800M
Dividends paid - - - - -
Change to inventory 9.96M -21.07200M 2.45M -10.01100M -10.43700M
Change to account receivables -53.87900M -7.79800M -2.59500M -2.88100M -4.02500M
Sale purchase of stock 1.20M 7.93M 34.63M 29.41M -3.13500M
Other cashflows from financing activities -19.27600M -1.12000M -1.08700M 29.41M 13.90M
Change to netincome -6.43000M 2.46M 5.80M 8.07M 6.74M
Capital expenditures 65.76M 24.43M 26.71M 24.05M 14.66M
Change receivables -53.87900M -7.79800M -2.59500M -2.88100M -4.02500M
Cash flows other operating 0.46M -4.05400M -3.38600M -1.01700M -3.56900M
Exchange rate changes - - 0.26M -1.91700M 0.02M
Cash and cash equivalents changes 123.99M -22.37800M 9.33M 24.58M -41.38600M
Change in working capital -22.78500M -6.42200M -6.63100M -0.06200M -20.69800M
Stock based compensation 10.18M 7.15M 6.44M 6.47M 5.54M
Other non cash items 7.36M 73.20M 51.87M 49.41M 56.71M
Free cash flow -24.72900M 43.61M 54.38M 61.83M 49.18M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NEOG
Neogen Corporation		 -0.05 0.52% 9.65 676.00 16.00 2.89 0.85 3.66 18.02
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Neogen Corporation

620 Lesher Place, Lansing, MI, United States, 48912-1595

Key Executives

Name Title Year Born
Mr. John Edward Adent Pres, CEO & Director 1968
Mr. Steven J. Quinlan VP & CFO 1962
Mr. Douglas E. Jones COO & VP 1970
Sarah Demey Admin. Mang. NA
Ms. Amy M. Rocklin Ph.D. VP, Gen. Counsel & Corp. Sec. 1972
Ms. Julie A. Mann VP & Chief HR Officer 1965
Mr. John Edward Adent President, CEO & Director 1968
Mr. David H. Naemura Chief Financial Officer 1970
Dr. Robert S. Donofrio Ph.D. VP & Chief Scientific Officer 1975
Sarah Demey Administrative Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.